(HealthDay News) — Although research has suggested that statins used to treat cardiovascular disease may also reduce the risk of fracture, treatment with rosuvastatin does not reduce the risk of fracture among men and women with evidence of inflammation, according to a new study published online December 1 in JAMA Internal Medicine.
The study included men >50 years and women >60 years. The study volunteers were followed for up to five years, with a median follow-up of 1.9 years. Almost 18,000 older adults (17,802) were selected to take either rosuvastatin or placebo. Smoking rates, weight, exercise levels, alcohol intake, rates of hypertension, and fracture history were similar in both groups.
Of the 431 fractures during the study, 221 were among those taking rosuvastatin and 210 were among people taking the placebo, the researchers found.
“Our study does not support the use of statin drugs in the doses used for heart disease for the prevention of bone fractures,” lead researcher Jessica Peña, MD, MPH, an assistant professor of cardiology at Montefiore Medical Center and the Albert Einstein College of Medicine in New York City, told HealthDay.